Skip to content

Association Between ALDH2 Gene Polymorphism and Atrial Fibrillation

Association Between ALDH2 Gene Polymorphism and Atrial Fibrillation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05524142
Acronym
AAAF
Enrollment
200
Registered
2022-09-01
Start date
2022-05-20
Completion date
2024-06-30
Last updated
2022-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

atrial fibrillation, ALDH2

Brief summary

This study is a case-control study. In this study, 2ml of vein blood samples were collected from patients with atrial fibrillation undergoing radiofrequency ablation and those in the control group who underwent electrophysiological examination alone and confirmed no arrhythmia. The purpose of this study is to identify the relationship between the aldehyde dehydrogenase 2 (ALDH2) gene polymorphism and susceptibility to atrial fibrillation, and to explore the relationship between the genotype of ALDH2 SNP and the prognosis of patients with atrial fibrillation undergoing radiofrequency ablation.

Interventions

None listed

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Signed informed consent; * Age 18-85 years old, gender is not limited; ③ Case group: patients with clinical diagnosis of atrial fibrillation who underwent radiofrequency ablation; control group: patients with no arrhythmia confirmed by electrophysiological examination; ④ Able to communicate well with investigators and comply with the entire trial requirements.

Exclusion criteria

* Those who cannot understand or refuse to sign the informed consent or follow-up; ②Pregnant women, mentally retarded, mental/cognitive insufficiency and other possible vulnerable groups

Design outcomes

Primary

MeasureTime frameDescription
atrial fibrillation recurrence3 monthsatrial fibrillation recurrence

Countries

China

Contacts

Primary ContactYaping o Wang
yapingwang@zju.edu.cn+8613805725837

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026